help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 73, No. 3 503-510
doi:10.1210/jcem-73-3-503
Copyright © 1991 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SHEN, D.-C.
Right arrow Articles by REAVEN, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SHEN, D.-C.
Right arrow Articles by REAVEN, G. M.

Effect of Gemfibrozil Treatment in Sulfonylurea-Treated Patients with Noninsulin-Dependent Diabetes Mellitus*

DER-CHUNG SHEN, MARTIN M. T. FUH, SHYH-MING SHIEH, Y.-D. IDA CHEN and GERALD M. REAVEN

Department of Medicine and Clinical Research Center, Tri-Service General Hospital, National Defense Medical Center Taipei, Taiwan, Republic of China
The Department of Medicine, Stanford University School of Medicine Stanford, California 94305

Address all correspondence and requests for repritns to: D.-C. Shen, M.D., Division of Endocrinology and Metabolism, Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.

This study was initiated to 1) assess gemfibrozil’s ability to lower plasma triglyceride (TG) concentration in patients with NIDDM, and 2) determine whether this effect was associated with any changes in glycemic control. Measurements were made of mean hourly plasma glucose, insulin, TG, and FFA concentrations from 1200–1600 h in response to a test meal; hepatic glucose production (HGP); insulin-stimulated glucose uptake during a hyperinsulinemic glucose clamp study (MCR); and fasting plasma lipoprotein TG and cholesterol concentrations in 12 patients with NIDDM before and 3 months after gemfibrozil treatment. Although ambient plasma TG and FFA concentrations fell significantly, plasma glucose, insulin, HGP, and glucose MCR did not change. However, when patients were divided into two groups, those with fasting plasma glucose levels above 9 mmol/L (fair control) and those with levels below 9 mmol/L (good control), a different phenomenon was observed. Patients in fair control had significant decreases in mean hourly plasma concentrations of glucose (15.1 ± 1.7 to 12.6 ± 0.9 mmol/ L; P < 0.001), insulin (523 ± 59 to 471 ± 75 pmol/L; P < 0.001), FFA (652 ± 150 to 504 ± 76 µmol/L), and HGP (9.5 0.4 to 8.1 ± 0.4 µmol/kg·min; P < 0.005), and an increase in glucose MCR (2.63 ± 0.49 to 3.72 ± 0.54 mL/kgmin; P < 0.07) in association with a fall in TG from 6.9 ± 1.3 to 3.5 ± 0.9 mmol/L (P < 0.001). Although fasting low density lipoprotein cholesterol increased (1.8 ± 0.2 to 2.7 ± 0.2 mmol/L; P < 0.05), the ratio of total to high density liproprotein cholesterol decreased (6.84 ± 0.88 to 5.80 ± 1.05; P < 0.02). Despite a significant fall in mean hourly TG concentration (4.6 ± 0.7 to 3.8 ± 0.7 mmol/L; P < 0.001), neither insulin, FFA, HGP, nor glucose MCR changed in patients in good control. Furthermore, the mean hourly plasma glucose concentration increased from 9.2 ± 0.7 to 11.7 ± 1.4 mmol/L (P < 0.001). Low density lipoprotein cholesterol also increased in this group (1.9 ± 0.2 to 2.7 ± 0.2 mmol/L; P < 0.02), but, as before, the ratio of total to high density lipoprotein cholesterol decreased (8.15 ± 1.93 to 6.36 ± 1.03; P < 0.02).

* This work was supported in part by grants from the NIH (RR-7022 and DK-30732), the Nora Eccles Treadwell Foundation, and the National Science Council (NSC78-0412-13016-85), Taipei, Taiwan, Republic of China.

Received October 19, 1990.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Subramanian, M. A. DeRosa, C. Bernal-Mizrachi, N. Laffely, W. T. Cade, K. E. Yarasheski, P. E. Cryer, and C. F. Semenkovich
PPAR{alpha} activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1365 - E1371.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society